$GRDN

Guardian Pharmacy Services, Inc.

alphai earnings readSecond Quarter 2026 · AUG 6Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year GuidanceVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $GRDN in the last 7 days.

No SEC Form 4 filings for $GRDN in the last 30 days.

See all $GRDN insider activity →
Med

Guardian Pharmacy Services (GRDN) Q2 2026 Earnings Call Transcript

Guardian Pharmacy Services (GRDN) reported Q2 2026 revenue of $351.8 million, up 2% year over year, and adjusted EBITDA of $29.7 million, up 19%. Net income rose to $22.1 million. The company raised full-year 2026 guidance to $1.43 billion to $1.45 billion revenue and $129 million to $131 million adjusted EBITDA, citing underlying growth despite IRA pricing pressure.

Why is Guardian Pharmacy Services stock rallying today?

Guardian Pharmacy Services (NYSE:GRDN) rose 3.2% pre-open after reporting Q2 2026 results ahead of forecasts. Adjusted EPS was $0.29 vs $0.23 expected, and revenue was $351.8M, up 2% YoY. The company raised full-year 2026 revenue guidance to $1.43–$1.45B. Adjusted EBITDA rose 19% to $29.7M.

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

GRDN sentiment & insider activity

Recent GRDN coverage spans financial news, earnings and corporate actions.

What's driving GRDN

  • Guidance raise and improved profitability metrics are likely to support near-term sentiment, but H2 reported revenue is guided to decline low single digits due to IRA pricing reductions.

    fool.com · Aug 14, 2026

  • Raised full-year revenue guidance plus margin expansion after an EPS beat should support near-term estimates and sentiment, but IRA pricing headwinds remain a key risk.

    investing.com · Aug 7, 2026

  • Q2 beat and explicit full-year revenue range provide a fresh earnings-and-guidance catalyst for GRDN.

    local3news.com · Aug 7, 2026

  • Raised full-year guidance and improved profitability metrics suggest a positive earnings revision cycle, though IRA pricing headwinds remain a key swing factor.

    SEC EDGAR 8-K · Aug 6, 2026

  • The new Lexington site is a tangible expansion of Guardian’s LTC footprint in Kentucky, which could modestly improve revenue visibility and customer access.

    lanereport.com · Aug 4, 2026

alphai scores every news story that mentions GRDN with an AI model for sentiment and relevance, and aggregates insider trades from Guardian Pharmacy Services, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GRDN

Score
$GRDNMedAI 8/10

Guardian Pharmacy Services (GRDN) Q2 2026 Earnings Call Transcript

Guardian Pharmacy Services (GRDN) reported Q2 2026 revenue of $351.8 million, up 2% year over year, and adjusted EBITDA of $29.7 million, up 19%. Net income rose to $22.1 million. The company raised full-year 2026 guidance to $1.43 billion to $1.45 billion revenue and $129 million to $131 million adjusted EBITDA, citing underlying growth despite IRA pricing pressure.

$GRDNMedAI 8/10

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

$GRDNHigh

Guardian Pharmacy Services, Inc. (GRDN): Results of Operations and Financial Condition

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced toda

Guardian Pharmacy Services opens long-term care (LTC) pharmacy in Lexington

Guardian Pharmacy Services (NYSE: GRDN) said it opened its first Kentucky physical location, Guardian Pharmacy of Kentucky, in Lexington. The LTC pharmacy will serve assisted living, skilled nursing, behavioral health, and intellectual and developmental disability organizations statewide. The company cited increased demand and said the facility uses automation to prepare medications, led by Tom Mullaney as president.

$GRDNLow

Guardian Pharmacy Services, Inc. (GRDN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001802255 0001802255 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

$GRDNMed

Guardian Pharmacy Services Announces First Quarter 2026 Results and Revises Full-Year Guidance

Guardian Pharmacy Services has released its financial results for the first quarter of 2026, including key financial metrics like revenue and earnings per share. The company also announced a revision to its full-year 2026 financial guidance, reflecting updated expectations based on its performance and current market conditions. This adjustment provides an updated outlook for the remainder of the year.

$GRDNHigh

Raymond James raises Guardian Pharmacy shares price target on vaccine program strength

Raymond James raised its price target on Guardian Pharmacy Services Inc. (NYSE:GRDN) to $40 from $35, maintaining an Outperform rating after strong fourth-quarter 2025 results. The company exceeded revenue and adjusted EBITDA estimates, driven by its successful flu vaccine program. Guardian Pharmacy also raised its 2026 guidance for adjusted EBITDA to $120-124 million, reflecting continued growth and improved operational execution, leading Truist Securities to also increase its price target.

$GRDNMed

GRDN: Expanding market share in assisted living pharmacy through organic growth and disciplined M&A

Guardian Pharmacy Services, Inc. (GRDN) is expanding its 13% market share in the assisted living pharmacy sector. The company is achieving this through a strategy of organic growth, disciplined mergers and acquisitions, and a technology-enabled service model. Strong financial performance, high adoption rates, and proactive engagement with regulators are positioning GRDN for continued growth amidst favorable demographic trends.

Related tickers